I think, although the extension into non-ambulant patients was...

I think, although the extension into non-ambulant patients was perhaps a bit more touch-and-go than the broader label and full approval in ambulant patients. In terms of what it means for ATL1102,
I think the honest answer is ‘not much’. It is already very clear that Elevidys is far from a curative therapy. Fundamentally, these kids will still have DMD, and will therefore still need access to other therapies. If anything, I think it potentially enhances the need for therapies that can modulate the inflammatory dimension of the disease.
I was expecting something like this for Elevidys sooner or later, and i had already concluded that it didn’t much change the equation for ATL1102...

fair post HL

Like I’ve said
im not a scientist but have worked in science
My opinions are not mine but others which I share with everyone…
Yes
im surprised that FDA passed srp901
I have not switched opinions..
1) was rejected by FDA but passed by sympathetic panel.
2) shows no efficacy
3 )$3.2 million treatment

Show me where I said it was going to be good for PER if srp901 failed…
All I said if it failed it would br
ing more attention to Atl1102
and make Sarepta and other Exon skipping drugs think twice about combination therapy ..

As for the PER share price nothing has changed
Srp901 approved or not approved

i still love the PER story..$$
believe or not
it matters not to me








..